| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Ambrosia's sweet $100m round, and other biofinancings | ||
| Do | Immunovant's thyroid eye disease drug flunks pivotal trials | ||
| Do | AZ claims another win for Imfinzi in frontline liver cancer | ||
| Do | Threat of Trump's pharma tariffs looms again | ||
| Do | Alzheimer's biotech Korsana to go public via reverse merger | ||
| Mi | Lilly bags FDA okay for Wegovy pill rival orforglipron | ||
| Mi | DNA testing can help right racial imbalance in breast cancer | ||
| Mi | EMA seeks input on virtual alternative to animal test | ||
| Mi | Agios mulls early FDA filing for sickle cell therapy | ||
| Mi | FDA points to liver injury with Amgen's Tavneos | ||
| Mi | NHS to offer Wegovy to a million more people in England | ||
| Di | Novo hits back at rivals with cut-price Wegovy subscriptions | ||
| Di | Biogen swoops on Apellis with $5.6bn offer | ||
| Di | Eli Lilly makes $7.8bn takeover play for Centessa | ||
| Di | UCB brings first therapy for rare disease TK2d to EU | ||
| Di | AZ considers filings for long-acting Strensiq follow-up | ||
| Di | Blackstone closes record $6.3bn life sciences fund | ||
| Mo | Obesity-focused biotech Kailera joins IPO queue in US | ||
| Mo | One in four diabetics has undiagnosed heart failure; study | ||
| Mo | Amgen's BiTE for lung cancer backed for EU approval | ||
| 27.03. | Recordati gets €10.9bn takeover bid from private equity firm | ||
| 27.03. | Where others missed, AZ's IL-33 drug hits the mark in COPD | ||
| 27.03. | Touchdown for Rocket as its first gene therapy gets US okay | ||
| 27.03. | Novartis snaps up food allergy firm Excellergy for $2bn | ||
| 26.03. | Wave's stock wavers on obesity drug data |